Filtered By:
Infectious Disease: Hepatitis

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 297 results found since Jan 2013.

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research

PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication
A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes in vivo, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the ...
Source: Frontiers in Immunology - April 29, 2022 Category: Allergy & Immunology Source Type: research

Viruses, Vol. 14, Pages 657: HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
ung Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer. Functional HBV cure defined as hepatitis B surface antigen (HBsAg) loss and undetectable serum HBV DNA is associated with improved clinical outcomes in patients with chronic HBV infection. However, spontaneous loss of HBsAg is rare and occurs in only 1% of all HBsAg-positive individuals annually. Furthermore, the rate of functional cure with currently available antiviral therapy is eve...
Source: Viruses - March 22, 2022 Category: Virology Authors: Maryam Moini Scott Fung Tags: Review Source Type: research

RNA interference as a novel treatment strategy for chronic hepatitis B infection
Clin Mol Hepatol. 2022 Feb 17. doi: 10.3350/cmh.2022.0012. Online ahead of print.ABSTRACTChronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hep...
Source: Clinical and molecular hepatology - February 17, 2022 Category: Gastroenterology Authors: Rex Wan-Hin Hui Lung-Yi Mak Wai-Kay Seto Man-Fung Yuen Source Type: research

Associations of DDX60L With the Clinical Features and Prognosis of Hepatocellular Carcinoma
ConclusionWe found that the downregulation of DDX60L expression correlated with poor prognosis in patients with HCC, which may be independent of the HCV-related pathway. Furthermore, DDX60L significantly inhibited the proliferation of Hep3B cells, migration and invasion of Hep3B and HCCLM3 cells. Therefore, DDX60L can serve as a prognostic biomarker and therapeutic target for HCC.
Source: Frontiers in Oncology - February 11, 2022 Category: Cancer & Oncology Source Type: research

Silencing HBV transcription with SMC5/6: has a path been found?
Chronic hepatitis B virus (HBV) infection is maintained by the viral nuclear covalently closed circular DNA (cccDNA) that is the transcriptional template for HBV’s mRNAs. The cccDNA is durable during current therapies, but a functional cure for HBV infections will require stable, off-treatment silencing of any cccDNA remaining in the body after treatment cessation.1 The cccDNA is silenced naturally during infection by binding of the structural maintenance of chromosome 5/6 (SMC5/6) complex to the cccDNA, and HBV antagonises this silencing with the HBx protein that binds to SMC5/6 and triggers its proteasomal degradat...
Source: Gut - January 11, 2022 Category: Gastroenterology Authors: Tavis, J., Chauhan, R. Tags: Gut Commentary Source Type: research

Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo
Conclusion These results reveal that therapeutics abrogating all HBV transcripts including HBx promote epigenetic suppression of the HBV minichromosome, whereas strategies protecting the human hepatocytes from reinfection are needed to maintain cccDNA silencing.
Source: Gut - January 11, 2022 Category: Gastroenterology Authors: Allweiss, L., Giersch, K., Pirosu, A., Volz, T., Muench, R. C., Beran, R. K., Urban, S., Javanbakht, H., Fletcher, S. P., Lütgehetmann, M., Dandri, M. Tags: Open access, Gut Hepatology Source Type: research

NLRP3 Inflammasome Activation is a Prognostic Marker of Recovery in HEV-Infected Patients
This study highlighted the significance of upregulated NLRP3 inflammasome leading to increased production of IL-18 and IL-1β cytokines in sera of AVH patients. Thus, it indicated the role of Th1 response acting through the NLRP3 pathway which might have been helpful in the recovery of AVH patients. These promising results open multiple treatment avenues where specific inhibitors can be designed to modulate the progress of disease and its pathogenicity.PMID:34982235 | DOI:10.1007/s00284-021-02736-x
Source: Current Microbiology - January 4, 2022 Category: Microbiology Authors: Vikram Thakur Radha Kanta Ratho Mini P Singh Yogesh Chawla Sunil Taneja Source Type: research

Vitexin attenuates autoimmune hepatitis in mouse induced by syngeneic liver cytosolic proteins via activation of AMPK/AKT/GSK-3 β/Nrf2 pathway
In conclusion, vitexin ameliorated hepatic injury in EAH mice through activation of the AMPK/AKT/GSK-3β pathway and upregulation of the Nrf2 gene.PMID:34953801 | DOI:10.1016/j.ejphar.2021.174720
Source: European Journal of Pharmacology - December 26, 2021 Category: Drugs & Pharmacology Authors: Lei Zhang Dazhi Chen Yulu Tu Tiantian Sang Tongtong Pan Hongwei Lin Chao Cai Xiaozhi Jin Faling Wu Lanman Xu Yongping Chen Source Type: research